

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TransThera Sciences (Nanjing), Inc.
藥捷安康（南京）科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2617)

**GRANT OF SHARE AWARDS AND SHARE OPTIONS UNDER
THE H SHARE AWARD SCHEME**

Reference is made to (i) the circular of TransThera Sciences (Nanjing), Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) dated May 22, 2026 in relation to, among other things, the proposed adoption of the H Share Award Scheme (the “**Circular**”); and (ii) the announcement of the Company dated June 18, 2026 in relation to, among other things, the poll results of the extraordinary general meeting and the Shareholders’ approval of the H Share Award Scheme. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Circular.

Pursuant to Rule 17.06A, Rule 17.06B and Rule 17.06C of the Listing Rules, the Board announces that on July 24, 2026, the Company granted a total of 2,816,900 Share Awards and 2,442,000 Share Options, involving an aggregate of 5,258,900 H Award Shares, to 67 Employee Participants (the “**Grantees**”) in accordance with the terms of the H Share Award Scheme.

DETAILS OF GRANT OF H AWARD SHARES

The details of the grant of the H Award Shares are as follows:

Date of Grant: July 24, 2026

A summary of the Grantees and their grants are set out below:

Grantees	Number of Share Awards granted	Number of Share Options granted	Aggregate number of H Award Shares underlying the Awards
Dr. Frank Wu, a Director	Nil	300,000	300,000
Mr. Wu Di, a Director	150,000	450,000	600,000
65 other Employee Participants	2,666,900	1,692,000	4,358,900
Total	2,816,900	2,442,000	5,258,900

GRANT OF SHARE AWARDS

Number of Share Awards granted:	2,816,900 Share Awards involving 2,816,900 H Award Shares
Purchase price for the grant:	Nil
Closing price of H Shares on the Grant Date:	HK\$10.19 per H Share
Vesting period and vesting conditions:	Subject to the relevant Grantee remaining an Eligible Participant and the satisfaction of the applicable vesting conditions and performance targets set out in the relevant Award Letter, the Share Awards shall vest as follows: (a) 660,000 Share Awards shall vest immediately upon the Grant Date; (b) 400,000 Share Awards shall vest on the first anniversary of the Grant Date; and (c) 1,756,900 Share Awards shall vest in the following proportions:

Vesting Date	Number of Share Awards to vest	Percentage of the relevant Share Awards to vest
First anniversary of the Grant Date	527,070	30%
Second anniversary of the Grant Date	527,070	30%
Third anniversary of the Grant Date	702,760	40%

Taking into account the grant of the Share Awards to certain Grantees serves as a recognition of the Grantees' past contribution to the Group and the expected significant contribution they will make to the Group, the remuneration committee of the Board is of the view that a vesting period less than 12 months for the grant of the Share Awards to certain Grantees is appropriate for retaining, incentivizing and rewarding the Grantees, as well as encouraging the Grantees to continuously contribute to the operation, development and long-term success and growth of the Group, which is in line with the purpose of the H Share Award Scheme.

Performance targets:	The vesting of the Share Awards is subject to the achievement of certain performance targets, in particular, the passing of the performance appraisal in the relevant preceding period before the vesting of Award Shares. The achievement of the performance targets will be assessed by the Scheme Administrator in accordance with the relevant terms of the Award Letters. If the Scheme Administrator determines that any specified performance target has not been achieved, the corresponding unvested Share Awards will automatically lapse.
----------------------	--

GRANT OF SHARE OPTIONS

Number of Share Options granted:	2,442,000 Share Options to subscribe for 2,442,000 H Award Shares
Consideration for the Share Options granted:	Nil
Exercise Price:	HK\$10.44 per H Award Share, being not less than the highest of (i) the nominal value of an H Share; (ii) the closing price of the H Shares as stated in the daily quotations sheet issued by the Stock Exchange on the Grant Date; and (iii) the average closing price of the H Shares as stated in the daily quotations sheets issued by the Stock Exchange for the five Business Days immediately preceding the Grant Date
Closing price of the H Shares on the Grant Date:	HK\$10.19 per H Share
Exercise period of the Share Options granted:	Subject to the vesting of the Share Options, the Share Options may be exercised during the period commencing on the relevant Vesting Date and ending on the tenth anniversary of the Grant Date, subject to the terms of the H Share Award Scheme and the relevant Award Letter.

Vesting period and vesting conditions:

Subject to the relevant Grantee remaining an Eligible Participant and the satisfaction of the applicable vesting conditions and performance targets set out in the relevant Award Letter, the Share Options shall vest as follows:

Vesting Date	Number of Share Options to vest	Percentage of the Share Options to vest
First anniversary of the Grant Date	732,600	30%
Second anniversary of the Grant Date	732,600	30%
Third anniversary of the Grant Date	976,800	40%

Performance targets:

The vesting of the Share Options is subject to the achievement of certain performance targets, in particular, the passing of the performance appraisal in the relevant preceding period before the vesting of Share Options. The achievement of the performance targets will be assessed by the Scheme Administrator in accordance with the terms of the relevant Award Letters. If the Scheme Administrator determines that any specified performance target has not been achieved, the corresponding unvested Share Options will automatically lapse.

Clawback mechanism:
(applicable to both Share Awards and Share Options)

In the event that:

- (a) a Grantee ceases to be an Eligible Participant by reason of:
 - (i) termination of the Grantee's employment or contractual engagement with the Group for cause or without notice;
 - (ii) termination of the Grantee's employment or contractual engagement with the Group as a result of the Grantee having been charged, penalised or convicted of an offence involving the Grantee's integrity or honesty;
- (b) in the reasonable opinion of the Scheme Administrator, a Grantee has committed a serious breach of an internal policy or code of any member of the Group or agreement with any member of the Group, including the breach of a non-compete obligation imposed on the Grantee by the Group, and such breach is considered material;
- (c) in the reasonable opinion of the Scheme Administrator, a Grantee has engaged in serious misconduct or breaches the terms of the Scheme in any material respect;

- (d) in the reasonable opinion of the Scheme Administrator, an Award to the Grantee will no longer be appropriate and aligned with the purpose of the Scheme; or
- (e) the Company's financial statements for any period in which an Award was granted or vested are subsequently found to contain a material misstatement (whether or not restated), and the Scheme Administrator reasonably considers that the Award should not have been granted or should be adjusted on materially different term,

then the Scheme Administrator may make a determination at its absolute discretion that: (A) any Awards granted but not yet exercised shall immediately lapse, regardless of whether such Awards have vested or not, and (B) with respect to any H Shares delivered, or cash payment paid, to the Grantee pursuant to any Awards granted under the Scheme, the Grantee shall be required to transfer back to the Company or its nominee (1) the equivalent number of H Shares, (2) an amount in cash equal to the market value of such H Shares or the cash payment, or (3) a combination of (1) and (2).

REASONS FOR AND BENEFITS OF THE GRANT

The purposes of the H Share Award Scheme are (i) to provide the Company with a flexible means of attracting, remunerating, incentivising, retaining, rewarding, compensating and/or providing benefits to Eligible Participants; (ii) to align the interests of Eligible Participants with those of the Company and the Shareholders by providing the Eligible Participants with the opportunity to acquire proprietary interests in the Company and become Shareholders; and (iii) to encourage Eligible Participants to contribute to the long-term growth, performance and profits of the Company and to enhance the value of the Company and its Shares for the benefit of the Company and the Shareholders as a whole.

The Grant recognises the contributions made by the Grantees to the Group and provides them with an opportunity to acquire proprietary interests in the Company. The Scheme Administrator considers that the Grant will align the interests of the Grantees with those of the Company and the Shareholders, motivate the Grantees to continue contributing to the long-term growth and development of the Group and assist the Group in attracting and retaining talent. Accordingly, the Scheme Administrator considers that the Grant is consistent with the purposes of the H Share Award Scheme and is in the interests of the Company and the Shareholders as a whole.

NUMBER OF SHARES AVAILABLE FOR FUTURE GRANT

As at the date of this announcement and following the Grants, the number of H Shares available for future grants under the Scheme Mandate Limit is 35,532,963 H Shares, among which, the number of H Shares available for future grants under the Service Provider Sublimit is 4,079,186 H Shares.

LISTING RULE IMPLICATIONS

The grant of 300,000 Share Options to Dr. Frank Wu and the grant of 150,000 Share Awards and 450,000 Share Options to Mr. Wu Di have been reviewed and approved by the independent non-executive Directors in accordance with Rule 17.04(1) of the Listing Rules.

The Grant would not result in the Shares issued and to be issued in respect of all awards granted to each of Dr. Frank Wu and Mr. Wu Di in the 12-month period up to and including the date of the Grant representing in aggregate over 0.1% of the issued Shares (excluding Treasury Shares). As such, the Grant will not be subject to approval by the Shareholders pursuant to Rule 17.04(4) of the Listing Rules.

To the best of the Directors' knowledge, as at the date of this announcement, save as disclosed above, none of the Grantees is (i) a Director, chief executive or substantial Shareholder of the Company, or an associate of any of them; (ii) a participant with options and awards granted and to be granted exceeding the 1% individual limit under the Listing Rules; or (iii) a Related Entity Participant or Service Provider Participant. No financial assistance will be provided by the Company to the Grantees to facilitate the acquisition of H Award Shares pursuant to the Share Awards or the exercise of the Share Options under the H Share Award Scheme.

By order of the Board
TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司
Dr. Frank Wu
Chairman and Chief Executive Officer

Hong Kong, July 24, 2026

As at the date of this announcement, the Board comprises: (i) Dr. Frank Wu and Mr. Wu Di as executive directors; (ii) Ms. Jia Zhongxin as a non-executive director; and (iii) Ms. Chui Hoi Yam, Mr. Feng Weibo and Mr. Li Shu Pai as independent non-executive directors.